全文获取类型
收费全文 | 29710篇 |
免费 | 2268篇 |
国内免费 | 69篇 |
专业分类
耳鼻咽喉 | 174篇 |
儿科学 | 1082篇 |
妇产科学 | 911篇 |
基础医学 | 4279篇 |
口腔科学 | 803篇 |
临床医学 | 3877篇 |
内科学 | 5255篇 |
皮肤病学 | 438篇 |
神经病学 | 3315篇 |
特种医学 | 525篇 |
外国民族医学 | 2篇 |
外科学 | 2743篇 |
综合类 | 309篇 |
一般理论 | 49篇 |
预防医学 | 3625篇 |
眼科学 | 467篇 |
药学 | 2143篇 |
中国医学 | 51篇 |
肿瘤学 | 1999篇 |
出版年
2023年 | 235篇 |
2022年 | 262篇 |
2021年 | 591篇 |
2020年 | 443篇 |
2019年 | 685篇 |
2018年 | 736篇 |
2017年 | 593篇 |
2016年 | 596篇 |
2015年 | 649篇 |
2014年 | 971篇 |
2013年 | 1425篇 |
2012年 | 1996篇 |
2011年 | 2061篇 |
2010年 | 1105篇 |
2009年 | 1067篇 |
2008年 | 1727篇 |
2007年 | 1816篇 |
2006年 | 1827篇 |
2005年 | 1730篇 |
2004年 | 1657篇 |
2003年 | 1493篇 |
2002年 | 1431篇 |
2001年 | 415篇 |
2000年 | 397篇 |
1999年 | 409篇 |
1998年 | 310篇 |
1997年 | 283篇 |
1996年 | 205篇 |
1995年 | 216篇 |
1994年 | 168篇 |
1993年 | 194篇 |
1992年 | 262篇 |
1991年 | 279篇 |
1990年 | 253篇 |
1989年 | 241篇 |
1988年 | 234篇 |
1987年 | 237篇 |
1986年 | 225篇 |
1985年 | 226篇 |
1984年 | 158篇 |
1983年 | 186篇 |
1982年 | 151篇 |
1981年 | 140篇 |
1980年 | 130篇 |
1979年 | 150篇 |
1978年 | 131篇 |
1977年 | 120篇 |
1976年 | 101篇 |
1974年 | 98篇 |
1973年 | 96篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
9.
Marie Warrer Petersen Tine Sylvest Meyhoff Marie Helleberg Maj-Brit Nørregaard Kjær Anders Granholm Carl Johan Steensen Hjortsø Thomas Steen Jensen Morten Hylander Møller Peter Buhl Hjortrup Mik Wetterslev Gitte Kingo Vesterlund Lene Russell Vibeke Lind Jørgensen Klaus Tjelle Thomas Benfield Charlotte Suppli Ulrik Anne Sofie Andreasen Thomas Mohr Morten H. Bestle Lone Musaeus Poulsen Mette Friberg Hitz Thomas Hildebrandt Lene Surland Knudsen Anders Møller Christoffer Grant Sølling Anne Craveiro Brøchner Bodil Steen Rasmussen Henrik Nielsen Steffen Christensen Thomas Strøm Maria Cronhjort Rebecka Rubenson Wahlin Stephan Jakob Luca Cioccari Balasubramanian Venkatesh Naomi Hammond Vivekanand Jha Sheila Nainan Myatra Christian Gluud Theis Lange Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375
Introduction
Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.Methods
The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.Discussion
The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.10.
Mary Ann Richardson Helen M Chao Laura L Read James D Clelland Raymond F Suckow 《American journal of medical genetics. Part B, Neuropsychiatric genetics》2006,(2):195-197
Phenylketonuria (PKU), an inborn error of phenylalanine metabolism, has been shown to be a risk factor for tardive dyskinesia (TD). In male psychiatric patients there was a significant relationship between TD and measures of plasma phenylalanine following ingestion of a standardized phenylalanine dose that was indicative of higher brain availability of phenylalanine in patients with TD. In addition, a medical food formulation consisting of branched chain amino acids, which compete with phenylalanine for transport across the blood-brain barrier, has been demonstrated to be an efficacious treatment for TD. Cumulatively these findings suggested that TD was related to phenylalanine metabolism and thus that sequence variants in the gene for phenylalanine hydroxylase (PAH), the rate-limiting enzyme in the catabolism of phenylalanine, could be associated with TD susceptibility. Genetic screening of PAH in a group of 123 psychiatric patients revealed ten sequence polymorphisms and two mutations, but none appeared to be a significant risk factor for TD. 相似文献